Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Announces Validation of US Patent


Santaris Pharma announced this week that the US Patent and Trademark Office has issued a inter partes re-examination certificate for a US patent held by the company and covering locked nucleic acids.

According to the company, the USPTO ruling upholds the claims within the patent, which had been the subject of re-examination proceedings initiated at the request of Isis Pharmaceuticals.

The patent in question, No. 6,770,748, is a continuation-in-part of another US patent that had also previously been the subject of an Isis re-examination request, according to Santaris.

"We are delighted that these lengthy procedures have been successfully concluded with USPTO confirming the patentability of our … patents,” Santaris President and CEO Henrik Stage said in a statement. “These are two of our fundamental patents, which provide broad protection for our … antisense drug platform based on the locked nucleic acid/bicyclic nucleic acid chemistries."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.